Lymphomatoid papulosis

Thomsen, Kristian

doi:10.1001/archderm.113.2.232b

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scarisbrick et al [ 23 ] treated 2 of 4 patients with 8 Gy in 2.0 Gy fractions; although there was a 50% CR rate, the first patient showed a CR with an additional 8 Gy. The remainder of studies lacked sufficient information on total dose, fractionation scheme, technique, or follow-up [ 3 , 21 , 24 ]. In our study, there was a 100% CR rate, supporting our data for single-fraction RT for palliation of CD30 + LPD.…”

Section: Discussionmentioning

confidence: 99%

Single-Fraction Radiotherapy for CD30⁺Lymphoproliferative Disorders

Gentile

Martínez-Escala

Thomas

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Objectives. CD30+ lymphoproliferative disorder is a rare variant of cutaneous T-cell lymphoma. Sustained complete response following first-line treatments is rare. This retrospective review evaluates the response of refractory or recurrent lesions to palliative radiation therapy. Methods. The records of 6 patients with 12 lesions, treated with radiation therapy, were reviewed. All patients received previous first-line treatments. Patients with clinical and pathological evidence of symptomatic CD30+ lymphoproliferative disorder, with no history of other cutaneous T-cell lymphoma variants, and with no prior radiation therapy to the index site were included. Results. The median age of patients was 50.5 years (range, 15–83 years). Median size of the treated lesions was 2.5 cm (range, 2–7 cm). Four sites were treated with a single fraction of 750–800 cGy (n = 3) and 8 sites were treated with 4000–4500 cGy in 200–250 cGy fractions (n = 3). Radiation therapy was administered with electrons and bolus. Median follow-up was 113 months (range, 16–147 months). For all sites, there was 100% complete response with acute grade 1-2 dermatitis. Conclusions. For recurrent and symptomatic radiation-naïve CD30+ lymphoproliferative disorder lesions, palliative radiation therapy shows excellent response. A single fraction of 750–800 cGy is as effective as a multifractionated course and more convenient.

show abstract

Section: Discussionmentioning

confidence: 99%

Single-Fraction Radiotherapy for CD30⁺Lymphoproliferative Disorders

Gentile

Martínez-Escala

Thomas

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Lymphomatoid papulosis can occur together with other dermatoses (Lutzner, Edelson & Schein, 1975;Thomsen & Schmidt, 1977). Two of the present patients (K.K.…”

Section: Discussionmentioning

confidence: 67%

DNA analysis by flow cytometry in lymphomatoid papulosis

Wantzin¹,

Thomsen²,

Larsen³

et al. 1983

Clin Exp Dermatol

Self Cite

View full text Add to dashboard Cite

Summary DNA analysis by flow cytometry revealed normal DNA histograms in three patients (seven skin specimens) with ‘classical’ lymphomatoid papulosis, A fourth patient, also with a‘classical lynphomatoid papulosis, had an increased number of tetraploid nuclei (14%, and 28%). The fifth patient with recurrent tumours, no papules and a more malignant histology showed ancuploidy by sequential examinations (hyperdiploidy and hypertetraploidy) of three skin specimens.

show abstract

Lymphomatoid Papulosis

Willemze

1985

Dermatologic Clinics

View full text Add to dashboard Cite

Lymphomatoid papulosis is an unusual chronic skin disease characterized by the continuous appearance of papulonecrotic, nodular, and occasionally larger tumorous or plaque-like lesions showing histologic features suggestive of malignant lymphoma. The recognition of two histologic types of lymphomatoid papulosis, which are not distinct entities but represent the ends of a spectrum, has provided an explanation for the clinical and histologic variation and many of the current controversies in this disorder. These two types of lymphomatoid papulosis, called type A (or "histiocytic" type) and type B (or lymphocytic type), have been shown to be related to Hodgkin's disease and mycosis fungoides, respectively. Current evidence suggests that these conditions result from abnormal immune reactions to persistent and as yet unidentified antigens. This concept does not resolve the question of whether lymphomatoid papulosis is an inflammatory or malignant disease. In most patients, lymphomatoid papulosis runs a protracted but benign course. In others, however, it is associated with or develops into malignant lymphoma. Because reliable clinical and histologic criteria predictive of such a transition are lacking, all patients with lymphomatoid papulosis require close long-term follow-up.

show abstract

Lymphomatoid papulosis

Cited by 8 publications

References 0 publications

Single-Fraction Radiotherapy for CD30⁺Lymphoproliferative Disorders

Single-Fraction Radiotherapy for CD30⁺Lymphoproliferative Disorders

DNA analysis by flow cytometry in lymphomatoid papulosis

Lymphomatoid Papulosis

Contact Info

Product

Resources

About

Lymphomatoid papulosis

Cited by 8 publications

References 0 publications

Single-Fraction Radiotherapy for CD30+Lymphoproliferative Disorders

Single-Fraction Radiotherapy for CD30+Lymphoproliferative Disorders

DNA analysis by flow cytometry in lymphomatoid papulosis

Lymphomatoid Papulosis

Contact Info

Product

Resources

About

Single-Fraction Radiotherapy for CD30⁺Lymphoproliferative Disorders

Single-Fraction Radiotherapy for CD30⁺Lymphoproliferative Disorders